Citation Impact
Citing Papers
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production
2005 StandoutNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor
2007 StandoutNobel
Stability of person-specific blood-based infrared molecular fingerprints opens up prospects for health monitoring
2021 StandoutNobel
Concordant Regulation of Gene Expression by Hypoxia and 2-Oxoglutarate-dependent Dioxygenase Inhibition
2006 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
2010 StandoutNobel
EGFR Antagonists in Cancer Treatment
2008 Standout
Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
2008 Standout
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
2008 StandoutNature
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
A Double-Blind, Placebo-Controlled, Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer (MRC PR05 Trial)
2003
Epidermal growth factor-related peptides and their receptors in human malignancies
1995 Standout
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Erectile Dysfunction
2000 Standout
Regulatory T Cells in Cancer
2010
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Hypoxia and Inflammation
2011 Standout
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Renal-Cell Carcinoma
1996 Standout
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Differential response to transforming growth factor (TGF)-α and fibroblast growth factor (FGF) in human renal cell carcinomas of the clear cell and papillary types
2000
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
The urokinase-type plasminogen activator system in cancer metastasis: A review
1997 Standout
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
2001
Regulation of angiogenesis by hypoxia: role of the HIF system
2003 StandoutNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
Monoclonal antibodies to target epidermal growth factor receptor–positive tumors
2002
The microenvironment of the tumour–host interface
2001 StandoutNature
HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation
2003 Standout
An overview on 5α-reductase inhibitors
2009
Novel approaches in the therapy of metastatic renal cell carcinoma
2005
The VHL/HIF axis in clear cell renal carcinoma
2012 StandoutNobel
TGFβ in Cancer
2008 Standout
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
2013
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
Current strategies in the management of hormone refractory prostate cancer
2003
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
2002 StandoutNobel
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase
2007 StandoutNobel
Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
2008 StandoutNobel
Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice
2007 StandoutNobel
FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity
2001 StandoutNobel
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
2011 StandoutNobel
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells
2003
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Optical sensory arrays for the detection of urinary bladder cancer‐related volatile organic compounds
2018
Role of transforming growth factor-α in von Hippel– Lindau (VHL) −/− clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
2001
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Functional Intactness of Stimulatory and Inhibitory Autocrine Loops in Human Renal Carcinoma Cell Lines of the Clear Cell Type
1997
INTRACAVERNOUS INJECTION THERAPY FOR MALE ERECTILE DYSFUNCTION
1995
von Hippel-Lindau Disease
2006 StandoutNobel
Coexpression of transforming growth factor-alpha and épidermal growth factor receptor in capillary hemangioblastomas of the central nervous system.
1995
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
2002 StandoutNobel
Cancer Cell Imaging and Photothermal Therapy in the Near-Infrared Region by Using Gold Nanorods
2006 Standout
A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma
2004
The Impact of Open Radical Retropubic Prostatectomy on Continence and Lower Urinary Tract Symptoms: A Prospective Assessment Using Validated Self-Administered Outcome Instruments
2004
Fibronectin Stimulates Non–Small Cell Lung Carcinoma Cell Growth through Activation of Akt/Mammalian Target of Rapamycin/S6 Kinase and Inactivation of LKB1/AMP-Activated Protein Kinase Signal Pathways
2006
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Gene
2020
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
1998 StandoutNobel
Structural Basis for Tumor Pyruvate Kinase M2 Allosteric Regulation and Catalysis,
2005
Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
1998
Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis.
1995
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Mechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor kappa B Activity
2005
Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha.
1992
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
1995
TGF-β Promotes the Establishment of Renal Cell Carcinoma Bone Metastasis
2006
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
2008 Standout
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Altered expression of transforming growth factor-alpha in hereditary rat renal cell carcinoma.
1991
Works of Rainer Hofmann being referenced
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
2004
Is There a Need to Further Subclassify pT2 Renal Cell Cancers as Implemented by the Revised 7th TNM Version?
2010
Non-invasive Detection of Bladder Tumors Through Volatile Organic Compounds: A Pilot Study with an Electronic Nose
2018
Frequency and Gene Expression Profile of Regulatory T Cells in Renal Cell Carcinoma
2009
TGF-β1 in patients with renal cell carcinoma
2002
Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma
1996
Plasma Levels of Cellular Fibronectin in Patients with Localized and Metastatic Renal Cell Carcinoma
2004
Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel
2006
Complications of Transurethral Resection of the Prostate (TURP)—Incidence, Management, and Prevention
2006
399 IS THERE A NEED TO FURTHER SUBCLASSIFY PT2 RENAL CELL CANCERS AS IMPLEMENTED BY THE REVISED 7TH TNM VERSION?
2011
Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker?
2002
THE USE OF BISPHOSPHONATE FOR THE PALLIATIVE TREATMENT OF PAINFUL BONE METASTASIS DUE TO HORMONE REFRACTORY PROSTATE CANCER
2001
Pelvic Floor Exercises, Electrical Stimulation and Biofeedback After Radical Prostatectomy: Results of a Prospective Randomized Trial
2003
Purulent Corporeal Cavernositis Secondary to Papaverine-Induced Priapism
1991
Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas.
1990